Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Financial News

Rodin raises $27M series B

Virginia Li
September 18, 2017 11:05 AM UTC

Rodin Therapeutics Inc. (Cambridge, Mass.) raised $27 million in a tranched series B round from existing investor Atlas Venture and new investors GV, Hatteras Venture Partners, Remeditex Ventures and Third Point Ventures. Details regarding the tranches are not disclosed.

Rodin is developing selective HDAC2 inhibitors to treat neurological disorders. The company plans to select a lead candidate this year and bring it into the clinic in 2018 to treat cognitive impairment in Alzheimer's disease (see BioCentury Innovations, April 14, 2016). ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Rodin Therapeutics Inc.

BCIQ Target Profiles

Histone deacetylase 2 (HDAC2)